STOCK TITAN

Know Labs - KNW STOCK NEWS

Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.

Overview

Know Labs Inc is a cutting-edge medical diagnostic company that specializes in the development of non-invasive testing technologies using proprietary Bio-RFID and ChromaID systems. These technologies leverage electromagnetic energy to capture the unique signature of substances, enabling the detection and identification of biomarkers without the need for conventional invasive procedures. By driving innovation in the field of healthcare diagnostics, Know Labs is committed to providing alternatives that enhance patient experience and streamline clinical operations.

Core Technologies and Innovations

Know Labs Inc has developed two main technologies that define its product offerings:

  • Bio-RFID Technology: This technology uses electromagnetic signals to record distinct bio-signatures from various substances, allowing for accurate identification and authentication. It offers a non-invasive approach, minimizing discomfort while delivering precise diagnostic information.
  • ChromaID Technology: Utilizing advanced spectral analysis, ChromaID captures the chromatic signature of materials, facilitating their detection and verification in a manner that bypasses traditional, more invasive methods.

These innovations not only represent significant advancements in diagnostic testing but also hold the potential to redefine standard practices within the medical field.

Applications in Medical Diagnostics

The technologies developed by Know Labs Inc are applicable to a wide range of diagnostic scenarios. A primary focus is on the development of wearable devices that integrate these technologies, such as non-invasive blood glucose monitors. This approach aims to eliminate the need for traditional fingerstick testing, thereby reducing patient discomfort and improving adherence to monitoring regimens. The practical applications of such tools extend beyond diabetes management to potentially encompass a variety of diagnostic uses where traditional methods are cumbersome or invasive.

Market Position and Industry Context

Operating in the competitive healthcare technology and medical diagnostics sector, Know Labs Inc carves out its niche by offering significantly disruptive non-invasive testing methods. Its emphasis on using electromagnetic energy to capture biomolecular signatures sets the company apart from traditional lab-based diagnostic systems. In doing so, Know Labs not only addresses critical challenges such as patient discomfort and procedural inefficiencies but also reinforces its position as a specialist in innovative diagnostic solutions within a rapidly evolving market.

Business Model and Revenue Considerations

The company’s business model centers on the research, development, and commercialization of its proprietary diagnostic technologies. Revenue generation is primarily achieved through the sales and marketing of medical devices and integrated diagnostic systems, along with potential licensing of its technologies to strategic partners. This model allows Know Labs Inc to expand the reach of its innovations throughout various segments of the healthcare industry, further solidifying its role as a transformative force in diagnostics.

Competitive Advantages and Industry Impact

Know Labs Inc distinguishes itself through its commitment to non-invasive, patient-friendly diagnostics. The use of sophisticated electromagnetic energy-based techniques provides an alternative to traditional, often cumbersome laboratory tests. This focus on innovation not only improves the accuracy and speed of diagnosis but also positions the company as a thought leader in the development of next-generation medical devices. The combination of its unique technologies and a strategically diversified product portfolio has the potential to influence the broader healthcare landscape significantly.

Detailed Technological and Clinical Insights

Understanding the technical nuances of Know Labs Inc's offerings requires an appreciation of both the scientific and practical aspects of its technologies. The Bio-RFID system relies on a precise interaction between electromagnetic waves and biological tissues, capturing signatures that are both unique and replicable. Similarly, the ChromaID system applies principles of spectral analysis to differentiate between subtle variations in material composition. Together, these systems exemplify how advanced technology can be harnessed to solve persistent challenges in clinical diagnostics. The integration of these innovations into wearable devices is poised to offer a practical, everyday application that can change how routine health monitoring is conducted.

News
Rhea-AI Summary
KNW: Know Labs, Inc. Appoints Three New Directors with Deep Sector Expertise. The company has named John Cronin, Larry Ellingson, and Tim Londergan to its Board of Directors. The new appointees bring extensive sector-relevant experience and deep knowledge of the science and marketplace focused on Know Labs, expanding the board to seven members. John Cronin, the founder and CEO of ipCapital Group, Inc., has played a pivotal role in increasing Know Labs' patent portfolio and global leadership in non-invasive blood glucose monitoring. Larry Ellingson, with 30 years at Eli Lilly, has been instrumental in shaping Know Labs' strategy and global relationships. Tim Londergan, founder and CEO of Tangibly, Inc., brings expertise in trade secret management and enhancing IP portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will present at the Bernstein CGM Disruptors Conference. The company has seen a 176% increase in patents issued, pending, and in process for non-invasive blood glucose monitoring. They have also published peer-reviewed reports on clinical results and completed production of their Generation 1 working prototype. The CFO will provide updates on the company's diagnostic technology platform and the path to bringing the first FDA-cleared non-invasive blood glucose monitor to the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Know Labs, Inc. announces pricing of public offering at $0.25 per share, expected to raise $7 million. Proceeds to be used for product development, clinical studies, and other expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.43%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
KNW - Know Labs, Inc. announced results from a new study demonstrating the improved accuracy of its proprietary Bio-RFID sensor technology for non-invasive blood glucose monitoring. The study validated algorithm performance and data preprocessing techniques, achieving an overall Mean Absolute Relative Difference (MARD) of 11.3%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none

FAQ

What is the current stock price of Know Labs (KNW)?

The current stock price of Know Labs (KNW) is $0.6999 as of April 1, 2025.

What is the market cap of Know Labs (KNW)?

The market cap of Know Labs (KNW) is approximately 1.8M.

What core technologies power Know Labs Inc's diagnostic solutions?

Know Labs Inc utilizes proprietary Bio-RFID and ChromaID technologies that leverage electromagnetic energy to capture unique bio-signatures for non-invasive diagnostics.

How do Know Labs' technologies improve patient care?

By offering non-invasive solutions, such as wearable devices for blood glucose monitoring, the company minimizes patient discomfort and streamlines diagnostic procedures.

What is the primary business focus of Know Labs Inc?

The company focuses on the development, marketing, and sales of innovative diagnostic devices that deliver accurate and non-invasive testing solutions for healthcare applications.

In which industry does Know Labs Inc operate?

Know Labs Inc operates in the medical diagnostics and healthcare technology sector, specifically targeting advancements in non-invasive testing methods.

How does Know Labs differentiate itself from traditional diagnostic methods?

Its unique approach using electromagnetic energy to record bio-signatures allows for more efficient and patient-friendly diagnostics compared to conventional invasive lab tests.

What potential applications arise from Know Labs' wearable diagnostic technology?

The wearable devices under development aim to measure critical health parameters, like blood glucose, non-invasively, thereby enhancing daily health monitoring and patient compliance.
Know Labs

NYSE:KNW

KNW Rankings

KNW Stock Data

1.80M
2.25M
19.93%
5.52%
2.24%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States
SEATTLE